| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2020 | CHEMOCENTRYX, INC. | 835 INDUSTRIAL RD | SAN CARLOS | CA | 94070 | SAN MATEO | USA | R01FD006342 | Phase 2 Study of Avacopan for Treatment of C3G, IND 132321, Orphan Designation 16-5590 | 001 | 2 | FDA | 6/1/2022 | $0 |
| | 2022 | 2020 | CHEMOCENTRYX, INC. | 835 INDUSTRIAL RD STE 600 | SAN CARLOS | CA | 94070-3312 | SAN MATEO | USA | R01FD006342 | Phase 2 Study of Avacopan for Treatment of C3G, IND 132321, Orphan Designation 16-5590 | 000 | 2 | FDA | 10/19/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $0 ) |
| | 2021 | 2020 | CHEMOCENTRYX, INC. | 835 INDUSTRIAL RD STE 600 | SAN CARLOS | CA | 94070-3312 | SAN MATEO | USA | R01FD006342 | Phase 2 Study of Avacopan for Treatment of C3G, IND 132321, Orphan Designation 16-5590 | 000 | 2 | FDA | 8/30/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $500,000 ) |
| | 2020 | 2020 | CHEMOCENTRYX, INC. | 850 MAUDE AVE | MOUNTAIN VIEW | CA | 94043-4022 | SANTA CLARA | USA | R01FD006342 | Phase 2 Study of Avacopan for Treatment of C3G, IND 132321, Orphan Designation 16-5590 | 000 | 2 | FDA | 8/27/2020 | $500,000 |
|
| Issue Date FY: 2019 ( Subtotal = $500,000 ) |
| | 2019 | 2019 | CHEMOCENTRYX, INC. | 850 MAUDE AVE | MOUNTAIN VIEW | CA | 94043-4022 | SANTA CLARA | USA | R01FD006342 | Phase 2 Study of Avacopan for Treatment of C3G, IND 132321, Orphan Designation 16-5590 | 000 | 1 | FDA | 9/10/2019 | $500,000 |
|
| Issue Date FY: 2016 ( Subtotal = $500,000 ) |
| | 2016 | 2016 | CHEMOCENTRYX INC | 1539 INDUSTRIAL ROAD | SAN CARLOS | CA | 94070 | SAN MATEO | USA | R01FD005414 | Phase 2 Studies of CCX168 for Treatment of ANCA-Vasculitis IND120784, OD14-4320 | 000 | 1 | FDA | 4/25/2016 | $500,000 |
|
| Issue Date FY: 2007 ( Subtotal = $3,124,002 ) |
| | 2007 | 2007 | CHEMOCENTRYX INC | 1539 INDUSTRIAL ROAD | SAN CARLOS | CA | 94070 | SAN MATEO | USA | U19AI056690 | CHEMOKINE ADJUVANTS FOR BIOTHREAT PATHOGEN VACCINES | 000 | 5 | NIH | 2/6/2007 | $3,124,002 |
|
| Issue Date FY: 2006 ( Subtotal = $3,157,823 ) |
| | 2006 | 2006 | CHEMOCENTRYX INC | 1539 INDUSTRIAL ROAD | SAN CARLOS | CA | 94070 | SAN MATEO | USA | U19AI056690 | CHEMOKINE ADJUVANTS FOR BIOTHREAT PATHOGEN VACCINES | 000 | 4 | NIH | 6/19/2006 | $3,157,823 |
|
| Issue Date FY: 2004 ( Subtotal = $3,088,117 ) |
| | 2004 | 2004 | CHEMOCENTRYX INC | 1539 INDUSTRIAL ROAD | SAN CARLOS | CA | 94070 | SAN MATEO | USA | U19AI056690 | CHEMOKINE ADJUVANTS FOR BIOTHREAT PATHOGEN VACCINES | 000 | 2 | NIH | 9/10/2004 | $3,088,117 |
|
| Issue Date FY: 2003 ( Subtotal = $1,273,008 ) |
| | 2003 | 2003 | CHEMOCENTRYX INC | 1539 INDUSTRIAL ROAD | SAN CARLOS | CA | 94070 | SAN MATEO | USA | U19AI056690 | CHEMOKINE ADJUVANTS FOR BIOTHREAT PATHOGEN VACCINES | 000 | 1 | NIH | 9/29/2003 | $1,273,008 |
|
| Issue Date FY: 2001 ( Subtotal = $99,999 ) |
| | 2001 | 2001 | CHEMOCENTRYX INC | 1539 INDUSTRIAL ROAD | SAN CARLOS | CA | 94070 | SAN MATEO | USA | R43AI048985 | A CMV VACCINE WITH MODIFIED IMMUNO-MODULATORY PROPERTIES | 000 | 1 | NIH | 9/10/2001 | $99,999 |
|
|
